Therapeutic Focus
Therapeutic Focus

Cardiovascular diseases are the leading cause of death globally, and high levels of LDL-C, or bad cholesterol, are the most readily modifiable risk factor in developing cardiovascular disease.

Read More
Innovative Science
Innovative Science

Small interfering RNA (siRNA) therapies harness a natural pathway to target the root causes of diseases and maintain their efficacy over a prolonged duration of time.

Read More
Clinical Development
Clinical Development

We’re focused on an investigational therapy being evaluated for its ability to produce clinically meaningful reductions in LDL-C, or bad cholesterol. We expect top-line data in Q3 2019.

Read More

The Medicines Company

The Medicines Company is a biopharmaceutical company whose purpose is to halt the deadly progression of atherosclerosis and the cardiovascular risk created by high levels of LDL-C, or bad cholesterol. Our team is focused on transformational solutions that address the daily challenges which patients, physicians and payers confront in cardiovascular care.
Learn More

Latest Tweets @MDCONews

  • The Medicines Company @MDCONews

    Among the key risk factors for #CVD are high blood pressure, high levels of LDL-C and smoking. What percentage of people in the U.S. have at least 1 of these 3 risks?

  • The Medicines Company @MDCONews

    Who is at risk for #ASCVD? Watch as cardiologist @ScottWrightMD explains some of the key risk factors associated with #CVD, and be sure to answer our quiz below! #CardioTwitter https://t.co/rcSYyfgM2u

More

Investors & Media

The Medicines Company has a proud tradition of leadership and a strong commitment to patients with cardiovascular disease. Our organization is focused on delivering great value to patients, physicians and shareholders through a potentially transformative therapy to lower LDL-C, or bad cholesterol.
Learn More

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com